RT Journal Article
SR Electronic
T1 Viral genome sequencing places White House COVID-19 outbreak into phylogenetic context
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.31.20223925
DO 10.1101/2020.10.31.20223925
A1 Bedford, Trevor
A1 Logue, Jennifer K.
A1 Han, Peter D.
A1 Wolf, Caitlin R.
A1 Frazar, Chris D.
A1 Pelle, Benjamin
A1 Ryke, Erica
A1 Lee, Jover
A1 Rieder, Mark J.
A1 Nickerson, Deborah A.
A1 Lockwood, Christina M.
A1 Starita, Lea M.
A1 Chu, Helen Y.
A1 Shendure, Jay
YR 2020
UL http://medrxiv.org/content/early/2020/11/01/2020.10.31.20223925.abstract
AB In October 2020, an outbreak of at least 50 COVID-19 cases was reported surrounding individuals employed at or visiting the White House. Here, we applied genomic epidemiology to investigate the origins of this outbreak. We enrolled two individuals with exposures linked to the White House COVID-19 outbreak into an IRB-approved research study and sequenced their SARS-CoV-2 infections. We find these viral sequences are highly genetically similar to each other, but are distinct from over 160,000 publicly available SARS-CoV-2 genomes, possessing 5 nucleotide mutations that differentiate this lineage from all other circulating lineages sequenced to date. We estimate this lineage has a common ancestor in the USA in April or May 2020, but its whereabouts for the past 5 to 6 months are not clear. Looking forwards, sequencing of additional community SARS-CoV-2 infections collected in the USA prior to October 2020 may reveal linked infections and shed light on its geographic ancestry. In sequencing of SARS-CoV-2 infections collected after October 2020, the relative rarity of this constellation of mutations may make it possible to identify infections that likely descend from the White House COVID-19 outbreak.Competing Interest StatementHYC is a consultant for Merck and GlaxoSmithKline. JS is a consultant with Guardant Health, Maze Therapeutics, Camp4 Therapeutics, Nanostring, Phase Genomics, Adaptive Biotechnologies, and Stratos Genomics, and he has a research collaboration with Illumina. All other authors declare no competing interests.Funding StatementThis work was supported by funding from the Brotman Baty Institute for Precision Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Individuals were enrolled as part of the HAARVI study. All participants completed informed consent. Previously collected samples, as well as prospectively collected samples, were used for this analysis. This study was approved by the University of Washington IRB (protocol #STUDY00000959).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesConsensus genome sequences and analysis code are available from https://github.com/blab/ncov-wh. https://github.com/blab/ncov-wh https://www.gisaid.org/